CASI Pharmaceuticals Stock Surges Amid Key Developments
By ATTN Desk · Editorial oversight: Sean Han
CASI Pharmaceuticals Inc. (NASDAQ: CASI)
1. Introduction
CASI Pharmaceuticals Inc. is a U.S.-listed biopharmaceutical company (ticker: CASI) involved in the development and commercialization of therapeutics for organ transplant rejection, autoimmune diseases, and oncology. Headquartered in Rockville, Maryland, with a wholly owned subsidiary in Beijing, CASI focuses on markets in Greater China and globally. As of June 13, 2025, the stock closed at USD 2.29, reflecting a price change of 27.93% on trading volume of 1,566,704 shares.
2. Corporate Structure and Experience
- Headquarters: Rockville, Maryland; subsidiary in Beijing, China
- Employees: 51–200 (LinkedIn data)
- Leadership:
- Wei-Wu He, Ph.D. – Chairman & Chief Executive Officer since 2019. Founder of Emerging Technology Partners and former CEO of OriGene. He has authored over 30 publications and holds 32 patents; he earned his Ph.D. from Baylor College of Medicine and his MBA from the Wharton School.
- Business Model: CASI in-licenses, acquires, and develops clinical-stage assets while leveraging its regulatory and commercial capabilities in China alongside U.S. drug development expertise.
3. Recent Developments and News
- June 13, 2025 – The stock price rose to USD 2.29 on a volume of 1.57 million shares.
- July 19, 2024 – A Form 6-K was filed detailing material updates regarding a dispute with Juventas concerning CNCT19, an autologous anti-CD19 T-cell therapy.
- February 20, 2024 – An amendment to Schedule 13D (SC 13D/A) reported that Sparkle Byte Limited holds 1,019,852 shares with sole voting power.
- October 27, 2020 – CASI entered into a licensing agreement with BioInvent for the development of BI-1206 (anti-FcγRIIB antibody) in Greater China, which includes an upfront payment of USD 12 million plus potential milestone payments totaling up to USD 83 million, along with tiered royalties.
4. Financial and Strategic Analysis
4.1 Key Financial Metrics (TTM, as of June 13, 2025)
| Metric | Value |
|---|---|
| Market Cap (intraday) | USD 35.3 million |
| 52-Week Range | USD 1.64–7.67 |
| Price/Sales (ttm) | 0.91 |
| Enterprise Value/Revenue | 1.07 |
| Revenue | USD 31.37 million |
| Net Income | –USD 40.48 million |
| Profit Margin | –129.05% |
| Return on Assets | –50.88% |
| Return on Equity | –1,094.50% |
| Total Cash (mrq) | USD 12.7 million |
| Diluted EPS | –2.54 |
4.2 Strategic Initiatives
- CID-103 (anti-CD38 mAb): In development to treat antibody-mediated rejection (AMR) in organ transplant patients as well as certain autoimmune diseases. Currently, there is no FDA-approved therapy for AMR, and peer-reviewed studies in the New England Journal of Medicine support the anti-CD38 approach in these contexts.
- CNCT19: An autologous anti-CD19 T-cell therapy being developed for B acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma, with ongoing resolution of a co-development dispute with Juventas.
- In-License Portfolio:
- EVOMELA® (melphalan injection) – approved by China’s National Medical Products Administration (NMPA)
- ZEVALIN® (ibritumomab tiuxetan) and MARQIBO® (liposomal vincristine) – in confirmatory trials in China
- Multiple FDA-approved abbreviated new drug applications (ANDAs)
5. Market Position and Industry Context
- Biopharma Space: CASI is classified as a small-cap company (beta 0.63) operating within the hematology oncology and immunology fields.
- Unmet Needs: AMR is reported to affect approximately 12% of kidney transplant recipients, representing more than 30,000 individuals in the U.S. without an approved treatment option.
- Competitive Landscape: The company's approach with anti-CD38 aims to differentiate from existing therapies targeting CD19 and CD20, which do not effectively deplete long-lived plasma cells.
- Geographic Focus: CASI leverages its operations in China for regulatory submissions and commercialization while retaining R&D capabilities in the U.S.
tl;dr
CASI Pharmaceuticals Inc.'s share price increased 27.93% on June 13, 2025, to USD 2.29 on significant trading volume. The company is advancing CID-103, an anti-CD38 treatment for antibody-mediated transplant rejection, without an existing FDA-approved standard of care, and progressing its CNCT19 T-cell therapy amid a development dispute with Juventas. Financials indicate USD 31.37 million in revenue, a net loss of USD 40.48 million, and USD 12.7 million in cash. Sparkle Byte Limited is reported to hold 1,019,852 shares. Future catalysts include clinical readouts for CID-103 and resolution of the CNCT19 collaboration.